Síndrome del seno carotídeo asociado a linfoma B cervical / Carotid sinus syndrome associated to cervical B-cell lymphoma

Resumen Se describe el caso de un varón de 75 años con tumoración submaxilar derecha de 5 meses de evolución sin diagnóstico etiológico, que consultó por episodios de síncope precedidos por disnea y sudoración profusa de instalación súbita. Durante su internación se detectaron, en el monitoreo electrocardiográ fico, pausas mayores a 3 segundos luego de la lateralización cervical reproduciendo los síntomas mencionados y asociadas a sensación de pérdida inminente de la conciencia, por lo que se implantó marcapasos transitorio. Se realizó biopsia de la masa tumoral cervical, consistente con linfoma B difuso de células grandes no centro germinal, y se inició quimioterapia. Luego de dicho tratamiento quimioterápico se observó reducción significativa de la masa tumoral con abolición de los síntomas asociados a las maniobras cervicales. El diagnóstico definitivo fue síndrome del seno carotídeo maligno asociado a linfoma cervical.

Abstract We present the case of a 75-year-old male with history of 5 months of right submaxillary tumor, with no clear etiology, who consulted for episodes of syncope preceded by dyspnea and sudden onset of profuse sweating. During his stay at the hospital, electrocardiographic records showed more than 3-second-long pauses after head movements, with a sensation of imminent loss of consciousness associated. A temporary pacemaker was required. Biopsy showed a diffuse non-germinal large B-cell B lymphoma, which required chemotherapy. After the first chemotherapy session, a significant reduction of the tumoral mass was observed, with abolition of the symptoms associated to cervical movements. The definitive diagnosis was malignant carotid sinus syndrome associated with cervical lymphoma.

[Carotid sinus syndrome associated to cervical B-cell lymphoma]. / Síndrome del seno carotídeo asociado a linfoma B cervical.

We present the case of a 75-year-old male with history of 5 months of right submaxillary tumor, with no clear etiology, who consulted for episodes of syncope preceded by dyspnea and sudden onset of profuse sweating. During his stay at the hospital, electrocardiographic records showed more than 3-second-long pauses after head movements, with a sensation of imminent loss of consciousness associated. A temporary pacemaker was required. Biopsy showed a diffuse non-germinal large B-cell B lymphoma, which required chemotherapy. After the first chemotherapy session, a significant reduction of the tumoral mass was observed, with abolition of the symptoms associated to cervical movements. The definitive diagnosis was malignant carotid sinus syndrome associated with cervical lymphoma.

Se describe el caso de un varón de 75 años con tumoración submaxilar derecha de 5 meses de evolución sin diagnóstico etiológico, que consultó por episodios de síncope precedidos por disnea y sudoración profusa de instalación súbita. Durante su internación se detectaron, en el monitoreo electrocardiográfico, pausas mayores a 3 segundos luego de la lateralización cervical reproduciendo los síntomas mencionados y asociadas a sensación de pérdida inminente de la conciencia, por lo que se implantó marcapasos transitorio. Se realizó biopsia de la masa tumoral cervical, consistente con linfoma B difuso de células grandes no centrogerminal, y se inició quimioterapia. Luego de dicho tratamiento quimioterápico se observó reducción significativa de la masa tumoral con abolición de los síntomas asociados a las maniobras cervicales. El diagnóstico definitivo fue síndrome del seno carotídeo maligno asociado a linfoma cervical.

Catheter ablation of ventricular tachycardia in patients with electrical storm, with a special focus on patients with Chagas disease.

BACKGROUND: There are few reports on the benefits of catheter ablation (CA) in patients with electrical storm (ES). None of these publications included patients with Chagas disease (ChD). Our aims are to analyze (1) all the cases of ES treated with CA and (2) the subgroup of patients with ChD. METHODS: Prospective analysis of consecutive patients with ES due to monomorphic ventricular tachycardia (VT) treated with CA. RESULTS: We included 38 patients: 28 males; median age of 63.5 (IQR 55-71) years old; ejection fraction (LVEF) 0.30 (0.25-0.40). Sixteen patients (42.1%) had ChD. The patients experienced 21 (15-37) VT episodes and received 7 (3-13) ICD shocks before CA. Forty-six procedures were performed (7 required epicardial access). All patients experienced ES suppression after CA. After 35 (10-64) months of follow-up (1.21 procedures per patient), 23 patients (60.5%) remain free from any VT; 35 patients (92.1%) were free from ES, and 11 patients (28.9%) died from non-arrhythmic causes. One patient underwent heart transplantation. Patients with ChD were younger (60 vs. 67 years old; p = 0.033), significantly more women (50% vs. 9.1%; p = 0.005), and had higher LVEF (0.40 vs. 0.28; p < 0.001) than the other patients. Long-term outcome of ChD patients was similar to that of the overall population. Only age and LVEF independently predicted mortality. CONCLUSION: CA was associated with acute ventricular arrhythmia suppression in all patients with ES. Freedom rates from ES and VT were 92.1% and 60.5% respectively. Despite having a lower-risk clinical profile, patients with ChD had a comparable outcome to that of the other patients.

Resultados del primer registro de implante de cardiodesfibriladores y resincronizadores SAC (RENCARE) / Results of the First SAC Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Registry (RENCARE)

RESUMEN Introducción: La prevención de la muerte súbita y el tratamiento de la insuficiencia cardíaca son temas de gran importancia. Para prevenir la muerte súbita y mejorar el pronóstico de la insuficiencia cardíaca se utilizan los cardiodesfibriladores y cardioresincronizadores. Objetivos: Evaluar la cantidad y tipo de dispositivos implantados en nuestro país, así como las características de los pacientes, las complicaciones agudas y las que se presentan en el seguimiento. Material y métodos: Se realizó un estudio observacional, prospectivo, multicéntrico en centros de salud con la capacidad de implantar cardiodesfibriladores y cardioresincronizadores. Se incluyeron pacientes a los que se les realizó implante de estos dispositivos desde enero del 2016 hasta enero de 2017, con un seguimiento de 12 meses. Resultados: Se incluyeron 249 pacientes (edad promedio de 64,8 ± 13,7 años, 73,9% de sexo masculino, 72,1% con Fey < 35%). La etiología subyacente de la miocardiopatía era isquémica en el 39,8%, dilatada 26,7% y chagásica en el 11,2% de los casos. El 58% de los implantes realizados fueron cardiodesfibriladores y el 39%, cardiodesfibriladores asociados con cardioresincronizadores. El 84% de los procedimientos fueron primoimplantes. La indicación más frecuente del implante fue por prevención primaria de muerte súbita (67,9%). La tasa de complicaciones menores fue del 4,4% y no se reportaron complicaciones mayores. Conclusiones: El siguiente registro evidenció una gran proporción de implantes en pacientes con cardiopatía isquémica, la indicación principal fue por prevención primaria de muerte súbita y la tasa de complicaciones fue similar a la reportada internacionalmente.

ABSTRACT Background: Prevention of sudden death and treatment of heart failure are very important topics. Implantable cardioverter-defibrillator and cardiac resynchronization devices are used to prevent sudden death and improve heart failure symptoms and prognosis. Objectives: The aim of this study was to evaluate the number, type of implanted devices, clinical characteristics of the patients and acute and follow-up complications. Methods: An observational, prospective, multicenter study was carried out in healthcare centers with the capacity to implant cardioverter-defibrillator and cardiac resynchronization devices. The study included all patients who underwent implantation of these devices from January 2016 to January 2017, with a 12-month follow-up. Results: A total of 249 patients (73.9% men) with mean age of 64.8±13.7 years, and 72.1% with ejection fraction <35%, were included in the study. The underlying cardiomyopathy etiology was ischemic in 39.8% of cases, dilated in 26.7% and chagasic in 11.2%. Fifty-eight percent of implants were implantable cardioverter-defibrillators and 39% were cardioverter-defibrillators associated with cardiac resynchronization devices. In 84% of cases, procedures were first implants. The most frequent indica-tion of implantation was for primary prevention of sudden death (67.9%). Minor complication rate was 4.4% and no major complications were reported. Conclusions: The present registry evidenced a large proportion of cardioverter-defibrillator and cardiac resynchronization implants in patients with ischemic heart disease. The main indication was for primary prevention of sudden death and the complication rate was similar to that reported internationally.